Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: July 27, 2023
Reporting Period: Second Quarter of 2023
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the second quarter of 2023. The detailed financial data is contained within the exhibits (Exhibit 99.1 and 99.2) incorporated by reference, rather than in the body of this 8-K.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are referenced but not included in the provided text.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. Investors must refer to the incorporated exhibits for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company posted a presentation on its website detailing financial and operating initiatives. This presentation includes references to non-GAAP financial information. Reconciliations between non-GAAP and GAAP measures are available in the Earnings Press Release.
Regulatory Note: Pursuant to General Instruction B.2, the information in Item 7.01 (including the presentation and press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities thereof, nor is it incorporated by reference into future filings unless specifically provided.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q2 2023 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Materials) for management's outlook and operating initiatives.
- Verify the reconciliation of non-GAAP financial measures to GAAP measures as stated in the press release.
- Confirm the status of the "Celgene Contingent Value Rights" (CELG RT) listed as a registered security.